Enoximone

Enoximone
Systematic (IUPAC) name

4-methyl-5-{[4-(methylsulfanyl)phenyl]carbonyl}-2,3-dihydro-1H-imidazol-2-one
Clinical data
AHFS/Drugs.com	International Drug Names
Legal status	UK: Prescription-only (POM)
Routes of administration	Intravenous
Pharmacokinetic data
Bioavailability	50% (oral)
Protein binding	85%
Metabolism	Hepatic oxidation
Half-life	4 to 10 hours
Excretion	Renal (60 to 70%)
Identifiers
CAS Registry Number	77671-31-9^Y
ATC code	C01CE03
PubChem	CID 53708
DrugBank	DB04880^Y
ChemSpider	48492^Y
UNII	C7Z4ITI7L7^Y
KEGG	D04004^Y
ChEMBL	CHEMBL249856^Y
Chemical data
Formula	C₁₂H₁₂N₂O₂S
Molecular mass	248.302 g/mol
SMILES O=C(/C1=C(/NC(=O)N1)C)c2ccc(SC)cc2
InChI InChI=1S/C12H12N2O2S/c1-7-10(14-12(16)13-7)11(15)8-3-5-9(17-2)6-4-8/h3-6H,1-2H3,(H2,13,14,16) ^Y Key:ZJKNESGOIKRXQY-UHFFFAOYSA-N ^Y
Y (what is this?) (verify)

Enoximone (INN, trade name Perfan) is an imidazole phosphodiesterase inhibitor. It is used in the treatment of congestive heart failure and is selective for phosphodiesterase 3.^[1]

References

↑ Boldt J, Suttner S (September 2007). "Combined use of ultra-short acting beta-blocker esmolol and intravenous phosphodiesterase 3 inhibitor enoximone". Expert Opin Pharmacother 8 (13): 2135–47. doi:10.1517/14656566.8.13.2135. PMID 17714066.

Phosphodiesterase inhibitors

PDE1	MMPX SCH-51866 Vinpocetine

PDE2	BAY 60-7550 EHNA

PDE3	Amrinone Anagrelide Bucladesine Cilostamide Cilostazol Enoximone KMUP-1 Milrinone Quazinone RPL-554 Siguazodan Trequinsin Vesnarinone Zardaverine

PDE4	Apremilast Arofylline Atizoram Cilomilast Denbutylline Drotaverine Etazolate Filaminast Glaucine HT-0712 Ibudilast ICI-63197 Irsogladine Luteolin Mesembrine Piclamilast Roflumilast Rolipram RPL-554 YM-976

PDE5	Acetildenafil Aildenafil Avanafil Dipyridamole Icariin Lodenafil Mirodenafil MY-5445 Nitrosoprodenafil Sildenafil Sulfoaildenafil T-0156 Tadalafil Udenafil Vardenafil

PDE6	Zaprinast

PDE7	BRL-50481

PDE9	BAY 73-6691 PF-04447943

PDE10	Papaverine PF-2545920 Tofisopam

PDE11	BC11-38

Nonselective	Caffeine Doxofylline IBMX Pentoxifylline Propentofylline Theophylline

Cardiac stimulants excluding cardiac glycosides (C01C)

Adrenergic and
dopaminergic agents

Adrenergic agonists

α	Metaraminol Phenylephrine Methoxamine Norfenefrine Oxedrine Midodrine Mephentermine

β	Dobutamine Arbutamine Isoprenaline Prenalterol

mixed	Amezinium metilsulfate Epinephrine # Norepinephrine Etilefrine

Dopamine agonists

Fenoldopam

Both

Unknown/ungrouped

Phosphodiesterase inhibitors (PDE3I)

Other cardiac stimulants

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

Index of the heart

Description	Anatomy Physiology Development

Disease	Injury Congenital Neoplasms and cancer Other Symptoms and signs eponymous Blood tests

Treatment	Procedures Drugs glycosides other stimulants antiarrhythmics vasodilators